ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly

• Angioedema associated with ACE-inhibitors can present with delayed onset, requiring heightened clinical awareness and vigilance beyond initial prescription periods
• Bradykinin-mediated angioedema (ACE-inhibitor induced) requires different management from histamine-mediated cases; ACE-inhibitor cessation is essential but antihistamines and corticosteroids are ineffective
• Accurate distinction between angioedema types is clinically critical as misidentification may lead to inappropriate treatment and delayed appropriate intervention

Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.